Literature DB >> 9809812

Novel aspects of gastrin-induced activation of histidine decarboxylase in rat stomach ECL cells.

D Chen1, C M Zhao, H Yamada, P Norlén, R Håkanson.   

Abstract

The ECL cells in the rat stomach respond to gastrin with secretion of histamine and activation of the histamine-forming enzyme histidine decarboxylase (HDC). In the present study, we have investigated factors that influence gastrin-induced activation of HDC. Gastrin-17 was given by continuous intravenous infusion to fasted and freely fed rats in various doses and for various periods of time. We found that: (1) ECL cells in fasted rats displayed one order of magnitude higher sensitivity to gastrin (3 h infusion) than did ECL cells in fed rats (ED50 0.4 versus 4.0 nmol kg(-1) h(-1)), while the maximum response to gastrin was two times greater in fed rats than in fasted rats; (2) HDC in both fasted and fed rats responded to a high gastrin dose (5 nmol kg(-1) h(-1)) in a biphasic manner with peak activity after 8 h in fasted rats and after 16 h in fed rats. In both groups, the activation was followed by a marked decline in the enzyme activity to almost prestimulation levels 24 h after start of the infusion. A low gastrin dose (0.4 nmol kg(-1) h(-1)) did not induce such a biphasic response. Maximum activation of HDC in fed rats occurred 6 days after starting the infusion of the low gastrin dose and was two times higher than the maximum activation observed after the high gastrin dose; (3) In fasted rats the HDC mRNA level rose in response to the high gastrin dose, peaked after 8 h (twofold increase) and then returned to the prestimulation level. In fed rats the increase was slower, reaching a plateau after 24 h that lasted for 6 days (twofold increase); (4) The translation inhibitor cycloheximide blocked the activation of HDC induced by gastrin (4 h infusion of 5 nmol kg(-1) h(-1)), while the transcription inhibitor actinomycin D, which suppressed the increase in HDC mRNA expression, did not.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9809812     DOI: 10.1016/s0167-0115(98)00111-6

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  7 in total

1.  Identification of a series of CCK-2 receptor nonpeptide agonists: sensitivity to stereochemistry and a receptor point mutation.

Authors:  Alan S Kopin; Edward W McBride; Ci Chen; Roger M Freidinger; Duan Chen; Chun-Mei Zhao; Martin Beinborn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-15       Impact factor: 11.205

2.  Ultrastructure of ECL cells in Mastomys after long-term treatment with H2 receptor antagonist loxtidine.

Authors:  Reidar Alexander Vigen; Mark Kidd; Irvin M Modlin; Duan Chen; Chun-Mei Zhao
Journal:  Med Mol Morphol       Date:  2012-06       Impact factor: 2.309

3.  Mobilization of rat stomach ECL-cell histamine in response to short- or long-term treatment with omeprazole and/or YF 476 studied by gastric submucosal microdialysis in conscious rats.

Authors:  T Konagaya; M Bernsand; P Norlén; R Håkanson
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

4.  Amino- and carboxy-terminal PEST domains mediate gastrin stabilization of rat L-histidine decarboxylase isoforms.

Authors:  J V Fleming; T C Wang
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

5.  Enhanced ghrelin expression and subsequent acid secretion in mice with genetic H(2)-receptor knockout.

Authors:  Mamoru Arakawa; Hidekazu Suzuki; Yuriko Minegishi; Yasushi Fukushima; Tatsuhiro Masaoka; Takashi Ishikawa; Hiroshi Hosoda; Kenji Kangawa; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2007-09-25       Impact factor: 7.527

6.  Immunocytochemical localization of monoamine oxidase type B in enterochromaffin-like cells of rat oxyntic mucosa.

Authors:  H Okauchi; S Nakajima; T Tani; A Ito; R Arai
Journal:  Histochem Cell Biol       Date:  2004-02-19       Impact factor: 4.304

Review 7.  Premises for Cholecystokinin and Gastrin Peptides in Diabetes Therapy.

Authors:  Jens F Rehfeld
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2019-12-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.